Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms
| Autor: | Franziska Scheiwein, Janusch Blautzik, Sonja Greven, Julia Sauerbeck, Kazunari Ishii, Sebastian Kotz, Peter Bartenstein, Andreas Delker, Axel Rominger, Matthias Brendel, Oliver Pogarell |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Gastroenterology 0302 clinical medicine Cognition Gray Matter 610 Medicine & health Depression (differential diagnoses) Aniline Compounds Depression General Neuroscience Amyloidosis digestive oral and skin physiology General Medicine Organ Size Magnetic Resonance Imaging Psychiatry and Mental health Clinical Psychology medicine.anatomical_structure Treatment Outcome Ethylene Glycols Female Superior Sagittal Sinus Selective Serotonin Reuptake Inhibitors medicine.medical_specialty Amyloid Grey matter behavioral disciplines and activities White matter 03 medical and health sciences Alzheimer Disease Internal medicine mental disorders medicine Humans Cognitive Dysfunction Effects of sleep deprivation on cognitive performance Aged business.industry medicine.disease 030227 psychiatry Positron-Emission Tomography Serotonin Geriatrics and Gerontology Atrophy Radiopharmaceuticals Reuptake inhibitor business 030217 neurology & neurosurgery Neuropsychiatric Inventory Questionnaire Follow-Up Studies |
| Zdroj: | Journal of Alzheimer's disease : JAD. 65(3) |
| ISSN: | 1875-8908 |
| Popis: | Late-life depression, even when of subsyndromal severity, has shown strong associations with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Preclinical studies have suggested that serotonin selective reuptake inhibitors (SSRIs) can attenuate amyloidogenesis. Therefore, we aimed to investigate the effect of SSRI medication on amyloidosis and grey matter volume in subsyndromal depressed subjects with MCI and AD during an interval of two years. 256 cognitively affected subjects (225 MCI/ 31 AD) undergoing [18F]-AV45-PET and MRI at baseline and 2-year follow-up were selected from the ADNI database. Subjects with a positive depression item (DEP(+); n = 73) in the Neuropsychiatric Inventory Questionnaire were subdivided to those receiving SSRI medication (SSRI(+); n = 24) and those without SSRI treatment (SSRI(-); n = 49). Longitudinal cognition (Δ-ADAS), amyloid deposition rate (standardized uptake value, using white matter as reference region (SUVRWM), and changes in grey matter volume were compared using common covariates. Analyses were performed separately in all subjects and in the subgroup of amyloid-positive subjects. Cognitive performance in DEP(+)/SSRI(+) subjects (Δ-ADAS: -5.0%) showed less deterioration with 2-year follow-up when compared to DEP(+)/SSRI(-) subjects (Δ-ADAS: +18.6%, p < 0.05), independent of amyloid SUVRWM at baseline. With SSRI treatment, the progression of grey matter atrophy was reduced (-0.9% versus -2.7%, p < 0.05), notably in fronto-temporal cortex. A slight trend towards lower amyloid deposition rate was observed in DEP(+)/SSRI(+) subjects versus DEP(+)/SSRI(-). Despite the lack of effect to amyloid PET, SSRI medication distinctly rescued the declining cognitive performance in cognitively affected patients with depressive symptoms, and likewise attenuated grey matter atrophy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|